Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults

A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK625433 in Healthy Subjects and in Subjects Who Are Chronically Infected With Hepatitis C.

This study represents the first administration of GSK625433 in humans. The study is designed to evaluate initial safety and tolerability in healthy adults as well as anti-viral activity in Hepatitis C(HVC) infected adults. The way the human body processes GSK625433 will also be investigated.

Inclusion criteria:

• Healthy males & females
• Part 1 ages 18-60
• Part 2 ages 18-50 & 65-80
• Within normal weight range given your height
• Negative urine drug and alcohol test
• Willing to follow all study procedures

Exclusion criteria:

• Any significant abnormal lab, ECG, medical or physical exam finding during screening
• Allergy to the study drug
• Excessive alcohol intake
• Positive HIV or hepatitis B or C result
• Use of prescription or non-prescription drugs within one week of study start except for birth control
• Blood pressure meds & Tylenol
• Pregnant or lactating women